Submit Deal

BAVARIAN NORDIC

HQ - Copenhagen

Summary

Bavarian Nordic is a biotechnology company that develops and manufactures vaccines for infectious diseases, including smallpox and cancer immunotherapies.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 2.54 B

Avg. Deal Size£ 1.27 B

Market Context

Senior Management

Paul Chaplin
President and CEO
Rolf Sass Sørensen
Vice President Investor Relations
Luc Debruyne
Chair

Sort

15 Feb 2023|United States|Biotechnology

Target: EMERGENT BIOSOLUTIONS (TRAVEL VACCINES PORTFOLIOS)

Bidder: BAVARIAN NORDIC

11 Service Providers

6 Bidder | 5 Vendor

36 Dealmakers

23 Bidder | 13 Vendor

£ 314 M

Value

28 Jul 2025|Denmark|Biotechnology

Target: BAVARIAN NORDIC

Bidder: NORDIC CAPITAL LTD

10 Service Providers

5 Target | 5 Bidder

19 Dealmakers

4 Target | 15 Bidder

£ 2.22 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy